Navigation Links
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Date:3/13/2008

NGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended Year ended

December 31, December 31,

2007 2006 2007 2006

Revenue $28 $86 $743 $273

Operating expenses:

Research and development 21,743 17,092 76,523 74,088

General and administrative 5,382 6,907 25,839 23,541

Total operating expenses 27,125 23,999 102,362 97,629

Loss from operations (27,097) (23,913) (101,619) (97,356)

Interest income 1,717 1,410 6,461 6,050

Interest expense (1,571) 1,017 (4,106) (336)

Ne
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo , ... Clinical Data Integration with EDC Systems ” at the ... on June 14th-18th. , During the presentation, Glenn Keet ... EDC, and will examine the value of patient engagement, ... health records/electronic medical records integration. , The presentation ...
(Date:5/28/2015)... MN (PRWEB) May 28, 2015 ... it a point to ask his audiences if ... future trends including robotics, solar cells, fuel cells, ... 3D printers, advanced battery storage technology, driverless cars, ... and high-quality but inexpensive online education. , ...
(Date:5/28/2015)... Rochelle, Virginia (PRWEB) May 28, 2015 ... Partners LLC announced today that Roger L. Williams, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:5/28/2015)... 2015 Clinerion, an eClinical ... and the Alliance for Clinical Research Excellence ... organization operating in the public interest and ... enhance quality, safety, integrity and operational effectiveness ... are pleased to announce their partnership for ...
Breaking Biology Technology:Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3
... Dec. 20 /PRNewswire-FirstCall/ - Athersys,Inc. (Nasdaq: ATHX ... announced today that Athersys has received authorization from ... a Phase I clinical trial,evaluating the safety of ... The companies believe that this represents the first,clinical ...
... access to ZEVALIN(R) and other novel ... ... by the House and Senate extends the 2007 reimbursement methodology,for ... had implemented new hospital outpatient reimbursement rates,for 2008 for radiopharmaceuticals ...
... abuse treatment for teens and adults, HIGHLANDS RANCH, ... the expansion of its treatment services to,include a detox ... 17 as well,as adults, and the hospital has added ... dual diagnosis (substance abuse and,mental illness)., Teen suicide ...
Cached Biology Technology:Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 2Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 3Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 4Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 5Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction 6House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 2House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 3Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2
(Date:5/25/2015)... , May 25, 2015  Australia,s market for ... stage, although 2014 saw the advent of several trials ... 24 April 2015 is expected to ignite interest in ... in Australia . This in turn ... industry and drive new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... , A group of Japanese researchers, who publish their findings ... Biomimetics , have succeeded in building a fully functional replica ... they have filmed their model butterfly flying. Among the ... wing area is very large relative to their body mass. ...
... to minimize the use of chemical herbicides need creative solutions ... research at the University of Illinois on Canada thistle, Sudangrass ... smother crop. "Sudangrass get very tall. It outcompetes the ... occur in the thistle," said U of I weed scientist ...
... NC Social status in paper wasps is established earlier ... month in the journal PLoS ONE . While ... appearance and are fixed from birth, paper wasp society is ... can climb the social ladder and become a queen. Now, ...
Cached Biology News:Sudangrass recommended to combat Canada thistle 2Sudangrass recommended to combat Canada thistle 3The making of a queen: Road to royalty begins early in paper wasps 2
... Each vial contains 200 g of lyophilized ... sequence (C-terminal amino acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. ... antigen for production of Cayman's EP1 receptor ... be used in conjunction with this antibody ...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Biology Products: